Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial.

Melatonin supplementation significantly improved atopic dermatitis severity as measured by the SCORAD index after 4 weeks.

• Participants received 10 mg melatonin tablet or matching placebo once daily for 4 weeks.
• SCORAD index improvement was statistically significant with p-value < 0.001.
• The study was a randomized, double-blind, placebo-controlled clinical trial.
• 80 patients completed the study, with mean age of 33.26 (SD 12.57) years and 40% male.

Melatonin supplementation significantly improved pruritus severity as measured by the Pruritus-NRS.

• Pruritus-NRS improvement was statistically significant with p-value of 0.006.
• Participants had mild to moderate atopic dermatitis at enrollment.
• Pruritus-NRS was assessed at baseline and after 4 weeks of supplementation.

Melatonin supplementation significantly improved sleep quality as measured by the ADSS and 12-PSS indices.

• ADSS improvement was statistically significant with p-value < 0.05.
• 12-PSS improvement was statistically significant with p-value of 0.011.
• Sleep quality outcomes were among the secondary endpoints of the trial.

Melatonin supplementation significantly improved quality of life as measured by the DLQI.

• DLQI improvement was statistically significant with p-value of 0.003.
• DLQI was assessed at baseline and after 4 weeks of supplementation.
• Quality of life was a secondary outcome of the trial.

Melatonin supplementation did not significantly improve pain intensity as measured by the NPRS.

• NPRS (Numeric Pain Rating Scale) improvement was not statistically significant with p-value of 0.063.
• Pain intensity was assessed as a secondary outcome alongside pruritus, sleep quality, and quality of life.
• This was the only secondary outcome that did not reach statistical significance.

No adverse effects were reported by any patient throughout the duration of the study.

• The dose used was 10 mg melatonin tablet once daily for 4 weeks.
• No patient reported an adverse effect throughout the study.
• 80 patients completed the study.